Elsevier

Brain Research

Volume 640, Issues 1–2, 21 March 1994, Pages 246-254
Brain Research

The CCKA receptor antagonist devazepide does not modify opioid self-administration or drug discrimination: comparison with the dopamine antagonist haloperidol

https://doi.org/10.1016/0006-8993(94)91880-5Get rights and content

Abstract

We previously reported that the selective cholecystokininA (CCKA) receptor antagonist, devazepide, blocked the acquisition of a morphine conditioned place preference (ref 28). An interpretation of this finding is that devazepide may either affect an opioid discriminative stimulus and/or modify the rewarding properties of opioids. The present study was designed to investigate these issues by determining the effect of equivalent doses of devazepide in a morphine drug discrimination paradigm and a model of heroin self-administration. In each case, devazepide (0.001–1 mg/kg) was ineffective, i.e there was no antagonism of a morphine discriminative cue, and in a separate group of rats trained to self-administer heroin (0.03 mg/kg/infusion, FR5 schedule, 1h per day), devazepide did not alter the pattern of heroin responding. Because of evidence implicating an interaction between accumbens CCK and dopamine (DA) systems and evidence suggesting an apparent differential involvement of DA in opioid place conditioning, self-administration and drug discrimination behaviour, the effect of the DA antagonist haloperidol was examined in the latter two paradigms. In each test, haloperidol produced an effect inconsistent with a direct DAergic involvement. In a final study the CCKB antagonist L365-260 was also found not to affect an opioid discriminative cue. The present results therefore cast doubt on the potential utility of selective CCKA antagonists as treatments for opioid abuse, and further suggest that CCKB antagonists may not potentiate the subjective effects of opioids, an important finding considering that such drugs have been proposed as adjuncts to opioid therapy for the treatment of pain relief.

Reference (75)

  • FuxeK. et al.

    Cholecystokinin peptides produce marked reduction of dopamine turnover in discrete areas in the rat brain following intraventricular injection

    Eur. J. Pharmacol.

    (1980)
  • GoedersN.E. et al.

    Self-administration of methionine enkephalin into nucleus accumbens

    Pharmacol. Biochem. Behav.

    (1984)
  • HarroJ. et al.

    CCK in animal and human research on anxiety

    TIPS

    (1993)
  • HeidbrederC. et al.

    Balance of glutamate and dopamine in the nucleus accumbens modulates self-stimulation behavior after injection of cholecystokinin and neurotensin in the rat brain

    Peptides

    (1992)
  • HigginsG.A. et al.

    Morphine place conditioning is differentially affected by CCKA and CCKB receptor antagonists

    Brain Res.

    (1992)
  • HillD.R. et al.

    Differentiation of central cholecystokinin receptor binding sites using the non-peptide antagonists MK-329 and L-365,260

    Brain Res.

    (1990)
  • HokfeltT. et al.

    A subpopulation of mesencephalic dopamine neurons projecting to limbic areas contains a cholecystokinin-like peptide: evidence from immunohistochemistry combined with retrograde tracing

    Neuroscience

    (1980)
  • HurdY.L. et al.

    Amphetamine regulation of mesolimbic dopamine/cholecystokinin neurotransmission

    Brain Res.

    (1992)
  • KoshikawaN. et al.

    Cholecystokinin octapeptide and caerulein injection into the dorsomedial nucleus accumbens potentiate apomophine-induced jaw movements in rats

    Eur. J. Pharmacol.

    (1991)
  • LeoneP. et al.

    Blockade of D-1 receptors by SCH23390 antagonizes morphine- and amphetamine-induced place preference conditioning

    Eur. J. Pharmacol.

    (1987)
  • LottiV.J. et al.

    A new potent and selective non-peptide gastrin antagonist and brain cholecystokinin receptor (CCKB) ligand: L-365,260

    Eur. J. Pharmacol.

    (1989)
  • MarleyP.D. et al.

    Effect of 6-hydroxydopamine lesions of the medial forebrain bundle on the distribution of cholecystokinin in rat forebrain

    Brain Res.

    (1982)
  • MoranT.H. et al.

    Two brain cholecystokinin receptors: implications for behavioural actions

    Brain Res.

    (1986)
  • MoserP.C.

    The effect of 5-HT3 receptor antagonists on the discriminative stimulus effects of amphetamine

    Eur. J. Pharmacol.

    (1992)
  • PhillipsA.G. et al.

    Dopaminergic mediation of reward produced by direct injection of enkephalin into the ventral tegmental area of the rat

    Life Sci.

    (1983)
  • PhillipsG.D. et al.

    Cholecystokinin-dopamine interactions within the nucleus accumbens in the control over behaviour by conditioned reinforcement

    Behav. Brain Res.

    (1993)
  • PrestonK.L. et al.

    Abuse liability studies of opioid-antagonists in humans

    Drug Alcohol Depend.

    (1991)
  • StolermanI.P. et al.

    Classification of opioid and 5-hydroxytryptamine receptors by means of discriminative stimulus drug effects

    Neuropharmacology

    (1987)
  • StudlerJ.M. et al.

    Pharmacological study on the mixed CCK8/DA meso-nucleus accumbens pathway: evidence for the existence of storage sites containing the two transmitters

    Brain Res.

    (1984)
  • VaccarinoF.J. et al.

    Antagonism of cholecystokinin function in the rostral and caudal nucleus accumbens: differential effects on brain stimulation reward

    Neurosci. Lett.

    (1989)
  • VickroyT.W. et al.

    Evidence that type A CCK receptors facilitate dopamine efflux in rat brain

    Eur. J. Pharmacol.

    (1988)
  • Bals-KubikR. et al.

    Neuroanatomical sites mediating the motivational effects of opioids as mapped by the conditioned place preference paradigm in rats

    J. Pharmacol. Exp. Ther.

    (1993)
  • BalsterR.L.

    Abuse potential of buspirone and related drugs

    J. Clin. Psychopharmacol.

    (1990)
  • BalsterR.L.

    Drug abuse potential evaluation in animals

    Br. J. Addiction

    (1991)
  • CarrG.D. et al.

    Conditioned place preference as a measure of drug reward

  • ChangR.S.L. et al.

    Biochemical and pharmacological characterization of an extremely potent and selective nonpeptide cholecystokinin antagonist

  • CorrigallW.A.

    A rodent model for nicotine self-administration

  • Cited by (35)

    • Medications development for food-based and drug use disorders

      2019, Advances in Pharmacology
      Citation Excerpt :

      These last findings are especially promising and deserve in-depth follow-up. Of note, CCK antagonists have been found to be without effect in opioid self-administration studies (Higgins, Joharchi, Wang, Corrigall, & Sellers, 1994), suggesting that their potential value as candidate medications for substance use disorder may be restricted to psychomotor stimulants like cocaine. Cocaine- and amphetamine-regulated transcript (CART) is a neuropeptide that is regulated by several gut peptides including leptin (Kristensen et al., 1998; Lee et al., 2013), ghrelin (de Lartigue, Dimaline, Varro, & Dockray, 2007), and CCK (Broberger, Holmberg, Kuhar, & Hökfelt, 1999; de Lartigue et al., 2007; Maletínská et al., 2008; for review, see Lau & Herzog, 2014).

    • A novel synthesis of pyrrolo[1,2-d][1,4]diazocines from tetrahydropyrrolo[1,2-a] pyrazines using activated alkynes in pyrazine ring expansion

      2010, Tetrahedron
      Citation Excerpt :

      In many cases their structures strongly resemble the whole composition of low-membered analogues in accordance to the fundamental bioisosteric rules.3 The few pathways towards benzoannulated pyrrolodiazocines include Ugi-type reaction and Dieckman condensation4 of adequately substituted pyrroles and a multi-step synthesis of fully hydrogenated pyrrolo[1,2-a][1,4]diazocines and pyrrolo[1,2-a][1,5]diazocines starting from proline and pyroglutamic acid.5 It was shown that pyrrolo[1,2-a][1,4]diazocines could be used as dipeptide reverse-turn mimetics6 exhibiting cognition enhancing activity.

    View all citing articles on Scopus
    1

    Present address: The Glaxo Unit of Behavioural Psychopharmacology, Division of Biosciences, University of Hertfordshire, College Lane, Hatfield, Herts. AL10 9AB, UK

    View full text